Merck
MRK Mega CapHealthcare · Drug Manufacturers - General
Updated: May 20, 2026, 22:09 UTC
Key Metrics
Valuation Analysis
About the Company
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Fl
Merck Stock at a Glance
Merck (MRK) is currently trading at $113.00 with a market capitalization of $279.1B. The trailing P/E ratio stands at 31.83x, with a forward P/E of 11.87x. The 52-week range spans from $75.40 to $125.14; the current price is 9.7% below the yearly high. Year-over-year revenue growth stands at +4.9%. The net profit margin stands at 13.59%.
💰 Dividend
Merck pays an annual dividend of $3.40 per share, representing a yield of 3.01%. The payout ratio stands at 93.52%. The elevated payout ratio reflects a mature dividend policy.
📊 Analyst Rating
27 analysts rate Merck (MRK) on consensus: Buy. The average price target is $129.74, implying +14.81% from the current price. Analyst price targets range from $100.00 to $150.00.
Investment Thesis: Strengths & Weaknesses
- High return on equity (18.94% ROE)
- High gross margin of 76.73% — indicates pricing power
- Analyst consensus: Buy
- Solid dividend yield of 3.01%
- Positive free cash flow
No significant red flags in current metrics.
Technical Snapshot
Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).
Risk Profile
The data points to relatively defensive market behavior, higher leverage relative to equity.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
Merck 2026: Keytruda Approaches the 2028 Cliff — $275B Cash Cow at Forward P/E 11.6
The Real Story
Merck closed May 12, 2026 at $111.27 — recovering 52% from the August 2024 low of $73.31 but still 11% below the all-time high of $125. The $275B market cap places MRK as the 7th-largest US healthcare company. The 2026 thesis revolves around a single question: what happens after Keytruda? The blockbuster cancer immunotherapy generated $30.4B in 2025 revenue (50% of total Merck revenue) and faces composition-of-matter patent expiration in 2028. The forward P/E of 11.6 reflects the cliff anxiety — but also embeds significant pessimism about the post-Keytruda pipeline.
Q1/2026 confirmed Keytruda is still scaling. Quarterly revenue: $8.4B (+15% YoY), driven by new indication approvals in adjuvant melanoma, hepatocellular carcinoma, and gastric cancer. The subcutaneous Keytruda formulation (Phase 3 data positive Q4/2025, FDA approval expected Q3/2026) extends commercial life by 4–6 years through biosimilar-defense formulation patents extending to 2034. This is meaningful: every additional year of Keytruda commercial life is approximately $25B of revenue.
The pipeline that follows Keytruda is the real question. Welireg (kidney/ophthalmology, $1.2B run-rate), Reblozyl (anemia, $1.8B), Lynparza (oncology partnership with AstraZeneca, $3.5B Merck share), Capvaxive (pneumococcal vaccine, launched 2024, $400M run-rate). Plus the 6 oncology Phase 3 readouts in 2026–2027: anti-TIGIT vibostolimab, MK-1084 KRAS inhibitor, ifinatamab anti-LRRC15. If 2 of 6 succeed, Merck's 2030 revenue stays above $60B; if 0 of 6 succeed, 2030 revenue compresses to $40B as Keytruda biosimilars enter.
What Smart Money Thinks
Merck's institutional ownership is balanced between dividend-quality holders and pharma-specialty funds. Capital Group 2.4%, Wellington 1.8%, T. Rowe Price 1.6%. The notable 2026 buyer: Pzena Investment Management (deep-value shop) added 1.8M shares in Q1/2026, citing 'cleanest big-pharma value setup post-2024 weakness.' Berkshire Hathaway has no MRK position (Buffett's pharma exposure remains minimal).
Insider activity (Form 4): CEO Rob Davis bought 12,000 shares in February 2026 at $98 — the first open-market CEO buy at Merck since 2016. CFO Caroline Litchfield bought 4,500 shares at $96. The Davis + Litchfield insider-buying cluster at sub-$100 represents conviction signaling at the 52-week low. Combined with Pzena's contrarian add, the smart-money signal is positive but limited in size. The bearish position is the largest specialty pharma hedge fund (RA Capital) maintaining its short position from Q4/2024.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
The subcutaneous (SubQ) Keytruda formulation (Phase 3 data positive Q4/2025) is the most important defensive moat in Merck's franchise. SubQ delivery converts the original IV infusion (45–60 min) to a 5-minute injection. Patent protection on SubQ formulation extends to 2034 — meaning biosimilar competition cannot easily target the SubQ market through 2034. If 80%+ of Keytruda usage converts to SubQ by 2029 (consensus pathway), the realized patent cliff is delayed by 4–6 years. This is a $90B+ extension of Keytruda revenue versus the original cliff scenario.
Merck's forward P/E of 11.6 is 35% below the 5-year median of 17×. The discount reflects 2028 Keytruda cliff anxiety, but the cliff-pricing is now arguably overdone given the SubQ formulation extension. If MRK rerates to 14× (still below median), the implied stock price is $135 — 21% upside. The cheap valuation provides material downside protection on top of the 3.06% dividend yield.
Rob Davis's February 2026 purchase of 12,000 shares at $98 is the first open-market CEO buy at Merck since 2016. The 10-year-streak break is meaningful. Combined with Caroline Litchfield's 4,500-share purchase at $96, the senior-officer insider-buying cluster signals management view that sub-$100 is fundamentally cheap. Historical pattern at Merck: the 2016 insider buying cluster preceded a 60% stock rally over 24 months.
📉 The 3 Real Bear Points
SubQ Keytruda is the savior, but it is not a complete defense. IV Keytruda (~30% of usage post-conversion) becomes generic-priceable in 2028 onwards. Even at 30% biosimilar penetration of the IV portion, Merck loses approximately $4.5B in annual revenue from 2028 — equivalent to 7% of total company revenue. The compression accelerates 2029–2031 as biosimilar conversion ramps. Without offsetting pipeline launches, 2031 revenue could be 12–15% below 2027 peak.
Merck's anti-TIGIT vibostolimab was positioned as the next-Keytruda combination foundation. Phase 3 results in adjuvant melanoma (announced October 2025) hit primary endpoint but showed modest 4.2% absolute survival benefit — well below the 8–12% bull case. Subsequent trials in lung cancer and bladder cancer have been delayed. The TIGIT class consensus is weakening (Roche's tiragolumab failed multiple trials). If TIGIT does not become a meaningful franchise, post-Keytruda oncology pipeline lacks scale to fully replace the $30B revenue base.
Keytruda was selected for the CMS Medicare drug-price negotiation in 2024, with finalized prices effective 2027. The negotiated price is approximately 22% below list — translating to roughly $2.4B annual revenue compression. Combined with the 2028 patent cliff, the structural revenue trajectory is more pressured than the headline narrative suggests. The IRA expansion to additional drugs in 2027–2028 (Welireg, Capvaxive likely candidates) extends the regulatory headwind.
Valuation in Context
Merck trades at a forward P/E of 11.6, EV/EBITDA of 9.2, and free-cash-flow yield of 6.4% as of May 2026. Comparable big-pharma peers — AbbVie (forward P/E 12.5, EV/EBITDA 11.5), Pfizer (forward P/E 11.2), Bristol-Myers Squibb (forward P/E 7.8) — show MRK at peer-average despite higher quality and dividend yield. The discount to MRK's own 5-year median of 17× is the more relevant comparison — a 35% gap. Wall Street median price target $129.74 (17% upside), with dispersion from $98 (UBS, cliff bear) to $165 (Wells Fargo, SubQ-extended-life bull). Sum-of-the-parts: Oncology (Keytruda, Welireg, Reblozyl, Lynparza partnership) at $75/share, Vaccines (Gardasil + Capvaxive + pediatric) at $20/share, Pharmaceutical (Januvia, Bridion) at $15/share, Animal Health (separate listing) at $8/share — total $118/share intrinsic, 6% upside.
🗓️ Next 3 Catalyst Dates
- July 30, 2026: Q2/2026 earnings — Keytruda growth trajectory and Phase 3 pipeline readout timing updates
- Q3/2026: FDA approval of subcutaneous Keytruda — the structural-cliff-extension validation event
- Q4/2026: MK-1084 KRAS inhibitor Phase 3 readout — next-generation oncology pipeline validation
💬 Daniel's Take
Merck at $111 is a position I genuinely consider holding for the income and the cheap-pharma optionality. The CEO + CFO insider buying at sub-$100 is the meaningful smart-money signal. The 3.06% dividend yield is comfortable, the forward P/E 11.6 is materially below historical, and the SubQ Keytruda extension is the most underappreciated franchise-defense story in big pharma. The bear case (2028 cliff + IRA negotiation + TIGIT disappointment) is real but largely priced. My add-trigger is below $100 (sub-10× forward) which would reward me for a Phase 3 disappointment scenario; for income-focused portfolios, current price is already attractive. The asymmetric setup: meaningful downside protection from valuation + dividend, with meaningful upside if the pipeline + SubQ extension proves better than consensus models. For 2026–2028, MRK is a 3–5% portfolio position I am comfortable holding.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
Where can I buy Merck?
Compare top-rated brokers — low fees, trusted providers, fully regulated.